Physician profile
Robert Selig Eagle
NPI 1922012335
$4,521.99
in general payments reported to CMS, 2019-2025
25 companies · $369 in 2025
The $369 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $843 · 2021: $762 · 2022: $754 · 2023: $396 · 2024: $620 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,384.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,343.66 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,040.97 | 2019-2025 | Skyrizi, Rinvoq, Creon |
| Ironwood Pharmaceuticals, INC | $411.64 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $396.23 | 2019-2025 | Entyvio |
| Braintree Laboratories, INC. | $192.65 | 2019-2023 | Suflave |
| Ardelyx, INC. | $188.61 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $186.61 | 2022-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $108.25 | 2019-2024 | Rebyota |
| Pfizer INC. | $88.40 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $78.47 | 2019-2022 | |
| Redhill Biopharma INC. | $64.81 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $59.50 | 2025 | Voquezna |
| Janssen Biotech, INC. | $54.93 | 2021-2022 | |
| Allergan, INC. | $54.48 | 2019 | |
| Genzyme Corporation | $41.04 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $38.13 | 2020 | |
| Evoke Pharma, INC. | $26.87 | 2021-2022 | |
| Olympus America INC. | $22.17 | 2024 | Evis X1 Video System Center |
| Alfasigma USA, INC. | $21.99 | 2020 | |
| Aimmune Therapeutics, INC. | $21.00 | 2025 | Zenpep |
| Medtronic, INC. | $20.93 | 2024 | Endoflip |
| Boston Scientific Corporation | $18.49 | 2024 | |
| Nestle Healthcare Nutrition INC. | $16.32 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.04 | 2019 | |
| Celgene Corporation | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Eagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.